[go: up one dir, main page]

BRPI0813966A8 - Usos de mdl-1 - Google Patents

Usos de mdl-1

Info

Publication number
BRPI0813966A8
BRPI0813966A8 BRPI0813966A BRPI0813966A BRPI0813966A8 BR PI0813966 A8 BRPI0813966 A8 BR PI0813966A8 BR PI0813966 A BRPI0813966 A BR PI0813966A BR PI0813966 A BRPI0813966 A BR PI0813966A BR PI0813966 A8 BRPI0813966 A8 BR PI0813966A8
Authority
BR
Brazil
Prior art keywords
cdm
mdl
antagonists
methods
relates
Prior art date
Application number
BRPI0813966A
Other languages
English (en)
Inventor
E Bigler Michael
J Cua Daniel
Joyce-Shaikh Barbara
H Phillips Joseph
Original Assignee
Schering Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Merck Sharp & Dohme filed Critical Schering Corp
Publication of BRPI0813966A2 publication Critical patent/BRPI0813966A2/pt
Publication of BRPI0813966A8 publication Critical patent/BRPI0813966A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

USOS DE MDL-1. A presente invenção refere-se a métodos para tratamento de distúrbios de reabsorção óssea com antagonistas de MDL-1.
BRPI0813966A 2007-06-29 2008-06-24 Usos de mdl-1 BRPI0813966A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94731407P 2007-06-29 2007-06-29
PCT/US2008/068042 WO2009006112A1 (en) 2007-06-29 2008-06-24 Mdl-1 uses

Publications (2)

Publication Number Publication Date
BRPI0813966A2 BRPI0813966A2 (pt) 2015-01-06
BRPI0813966A8 true BRPI0813966A8 (pt) 2016-02-10

Family

ID=39712082

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813966A BRPI0813966A8 (pt) 2007-06-29 2008-06-24 Usos de mdl-1

Country Status (10)

Country Link
US (2) US20100221252A1 (pt)
EP (1) EP2176294B1 (pt)
JP (2) JP5171948B2 (pt)
CN (1) CN101802011A (pt)
AU (1) AU2008270710A1 (pt)
BR (1) BRPI0813966A8 (pt)
CA (1) CA2691618A1 (pt)
ES (1) ES2540854T3 (pt)
WO (1) WO2009006112A1 (pt)
ZA (1) ZA201000393B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
JP5166398B2 (ja) 2006-04-07 2013-03-21 エアーピオ セラピューティクス インコーポレイテッド ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用
WO2011053630A1 (en) * 2009-10-30 2011-05-05 Schering Corporation Uses of a mammalian cytokine
PT2647707T (pt) 2010-11-30 2018-11-15 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de toxicidade
EP2675467A4 (en) * 2011-02-18 2014-06-25 Merck Sharp & Dohme USE OF MDL-1 ANTAGONISTS FOR THE TREATMENT OF SPONDYLARTHROPATHY
WO2013043516A1 (en) 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Mdl-1 ligand
EP2766044B1 (en) 2011-10-13 2019-12-11 Aerpio Therapeutics, Inc. Treatment of ocular disease
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
KR102398736B1 (ko) 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
DK2780373T3 (da) 2011-11-16 2019-11-04 Boehringer Ingelheim Int Anti-IL-36R-antistoffer
AU2015244814B2 (en) 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
EA201692287A1 (ru) 2014-05-13 2017-06-30 Чугаи Сеияку Кабушики Каиша Антигенсвязывающая молекула, перенаправляющая т-клетки на клетки, обладающие иммуносупрессорной функцией
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
TW202342540A (zh) 2016-03-14 2023-11-01 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
MX2020009544A (es) 2018-03-14 2020-10-05 Boehringer Ingelheim Int Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada.
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
WO2021006328A1 (en) 2019-07-10 2021-01-14 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
JP2023534955A (ja) 2020-07-17 2023-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体
CN115779071B (zh) * 2022-11-04 2024-12-24 济宁医学院附属医院 Mdl-1在制备缺血性脑卒中后脑保护药物中的应用
TW202517686A (zh) * 2023-07-13 2025-05-01 大陸商深圳澤安生物醫藥有限公司 多特異性抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416973B1 (en) * 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
WO2005027848A2 (en) * 2003-09-19 2005-03-31 Barnes-Jewish Hospital Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
AR059193A1 (es) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
JP2010526066A (ja) * 2007-04-23 2010-07-29 シェーリング コーポレイション 抗ｍｄｌ−１抗体

Also Published As

Publication number Publication date
CA2691618A1 (en) 2009-01-08
JP2010532369A (ja) 2010-10-07
JP5171948B2 (ja) 2013-03-27
ZA201000393B (en) 2014-03-26
WO2009006112A1 (en) 2009-01-08
EP2176294A1 (en) 2010-04-21
AU2008270710A1 (en) 2009-01-08
ES2540854T3 (es) 2015-07-14
JP2012233008A (ja) 2012-11-29
EP2176294B1 (en) 2015-05-20
BRPI0813966A2 (pt) 2015-01-06
CN101802011A (zh) 2010-08-11
US20100221252A1 (en) 2010-09-02
US20120177647A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
BRPI0813966A8 (pt) Usos de mdl-1
CR20110103A (es) Heteroarilos sustituidos
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
BRPI0916268A2 (pt) sistemas de fixação de fratura
LT3725329T (lt) Kaulų rezorbcijos slopinimo būdas
BR112012013260A2 (pt) dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
DE602007012072D1 (de) Orantagonisten
BR112012017051A2 (pt) método para diminuir a imunogenicidade
BRPI1008939A2 (pt) 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
DE112007000518A5 (de) Anlage zur Erzeugung von Elektrizität
NI200900148A (es) COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33536A
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
BRPI1006730A2 (pt) biomateriais de fosfato de cálcio com gálio
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI0822012A2 (pt) Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
BRPI0716532A2 (pt) compostos azabicÍclios como inidores de reabsorÇço de monoaminas
IL206359A0 (en) Sulfonamides as orexin antagonists
EP2253206A4 (en) COMPOSITION FOR COMBATING PLANT DISEASES
SE0800742L (sv) Vikttäcke
PA8782301A1 (es) Tratamiento de leucemia resistente al imatinte

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.